Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Integral Diagnostics Ltd. ( (AU:IDX) ) just unveiled an update.
Integral Diagnostics Ltd has notified the market of the cessation of 37,488 IDXAA long-term incentive performance rights, which were cancelled by agreement between the company and the holder effective 16 January 2026. The cancellation marginally reduces the company’s outstanding equity-based incentive securities, slightly simplifying its capital structure and potentially altering the alignment of incentives for the affected participant without indicating any broader operational or strategic shift at this stage.
The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
More about Integral Diagnostics Ltd.
Integral Diagnostics Ltd (ASX: IDX) is an Australian-listed company operating in the healthcare sector, primarily focused on diagnostic imaging services. The company provides radiology and related imaging solutions through its network, servicing patients, referrers and healthcare providers in its markets.
Average Trading Volume: 787,821
Technical Sentiment Signal: Sell
Current Market Cap: A$973.3M
For detailed information about IDX stock, go to TipRanks’ Stock Analysis page.